Argenica Therapeutics (ASX: $AGN) achieves significant milestone in Phase 2 stroke trial

Argenica Therapeutics Limited (ASX: $AGN) has successfully dosed five patients in its acute ischaemic stroke Phase 2 clinical trial, marking a significant achievement in the development of novel therapeutics to reduce brain tissue death after stroke and other neurological conditions.

Executive Commentary

We are extremely appreciative of the commitment the hospitals have shown in actively managing, recruiting, and dosing patients. To achieve dosing of the first safety cohort after less than two weeks is a testament to the dedication of the clinical trial teams working in the emergency departments of our trial sites. We look forward to providing ongoing updates on the recruitment and DSMB outcomes as the trial progresses.

Summary

Argenica Therapeutics (ASX: $AGN) has achieved a significant milestone by successfully dosing the first cohort of acute ischaemic stroke patients in its Phase 2 clinical trial of ARG-007. The trial aims to determine the safety, preliminary efficacy, and pharmacokinetics of ARG-007 in AIS patients, with the potential to progress to a pivotal Phase 3 trial and engage with global pharmaceutical companies. Additionally, the trial seeks to generate preliminary data on the ability of ARG-007 to reduce brain tissue death following stroke and mechanical removal of brain clot, positioning Argenica at the forefront of neuroprotective clinical validation. The company's dedication to developing novel therapeutics to improve patient outcomes in stroke and other brain injuries is evident in its ongoing Phase 2 clinical trial and preclinical data generation in various neurological conditions.